In the high-stakes race to find effective treatments for Alzheimer's and Parkinson's disease, Allyx Therapeutics has secured a fresh infusion of capital. The clinical stage biotechnology company announced it has closed a $26.5M Series B funding round.
Allyx's mission is to develop disease-modifying therapies by targeting the underlying cause of synapse dysfunction and loss. This strategic approach aims to move beyond merely managing symptoms, instead seeking to address the fundamental mechanisms driving these debilitating neurodegenerative conditions at their source.
